Sources
Key References
Spravato (esketamine)
Ketamine
Deep Transcranial Magnetic Stimulation
Ketamine Assisted Therapy
Spravato (esketamine)
Spravato (Esketamine) Key References
- PubMed Literature Search
- Araújo-de-Freitas L, Santos-Lima C, Mendonça-Filho E, Vieira F, França RJ, Magnavita G, Cardoso TL, Correia-Melo FS, Leal GC, Jesus-Nunes AP, Souza-Marques B. Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: a comparative, randomized and double-blind study. Psychiatry Research. 2021 Sep 1;303:114058.
- Canuso CM, Ionescu DF, Li X, Qiu X, Lane R, Turkoz I, Nash AI, Lopena TJ, Fu DJ. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. Journal of clinical psychopharmacology. 2021 Sep;41(5):516.
- Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry. 2018 Jul 1;175(7):620-30.
- Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MV, Bandeira ID, Silva SS, Cavalcanti DE. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. Journal of affective disorders. 2020 Mar 1;264:527-34.
- Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA psychiatry. 2019 Sep 1;76(9):893-903.
- Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology. 2019 Oct;22(10):616-30.
- Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). The Journal of clinical psychiatry. 2020 May 12;81(3):6605.
- Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). International Journal of Neuropsychopharmacology. 2021 Jan;24(1):22-31.
- Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B. Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression. Clinical Pharmacology & Therapeutics. 2021 Feb;109(2):536-46.
- Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological psychiatry. 2014 Dec 15;76(12):970-6.
- Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3. The American Journal of Geriatric Psychiatry. 2020 Feb 1;28(2):121-41.
- Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. American Journal of Psychiatry. 2019 Jun 1;176(6):428-38.
- Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biological psychiatry. 2016 Sep 15;80(6):424-31.
- Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC psychiatry. 2021 Dec;21(1):1-3.
- Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). The Journal of clinical psychiatry. 2020 Apr 28;81(3):10773.
Ketamine
Ketamine Key References
Major Depressive Disorder (MDD)
Treatment Resistant Depression (TRD)
- PubMed Literature Search
- Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, Thuras P, Batres-y-Carr TM, Wels J, Shiroma PR. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. The Journal of clinical psychiatry. 2018 May 1;79(3):17462.
- Araújo-de-Freitas L, Santos-Lima C, Mendonça-Filho E, Vieira F, França RJ, Magnavita G, Cardoso TL, Correia-Melo FS, Leal GC, Jesus-Nunes AP, Souza-Marques B. Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: a comparative, randomized and double-blind study. Psychiatry Research. 2021 Sep 1;303:114058.
- Chen MH, Wu HJ, Li CT, Lin WC, Tsai SJ, Hong CJ, Tu PC, Bai YM, Mao WC, Su TP. Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression. Asian Journal of Psychiatry. 2021 Dec 1;66:102869.
- Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MV, Bandeira ID, Silva SS, Cavalcanti DE. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. Journal of affective disorders. 2020 Mar 1;264:527-34.
- Domany Y, Bleich-Cohen M, Tarrasch R, Meidan R, Litvak-Lazar O, Stoppleman N, Schreiber S, Bloch M, Hendler T, Sharon H. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. The British Journal of Psychiatry. 2019 Jan;214(1):20-6.
- Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. American Journal of Psychiatry. 2021 Apr 1;178(4):352-62.
- Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, Beauchamp S. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. Journal of Affective Disorders. 2020 Dec 1;277:831-41.
- Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye O, Batten LA, Blier P. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. American Journal of Psychiatry. 2019 May 1;176(5):401-9.
- Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, Owoeye O, Batten LA, Blier P. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020 Mar;45(4):606-12.
- Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula connectivity and intravenous ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology. 2021 May;24(5):383-91.
- Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. American Journal of Psychiatry. 2016 Aug 1;173(8):816-26.
- Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017 Dec;42(13):2482-92
- Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of general psychiatry. 2006 Aug 1;63(8):856-64.
Generalized Anxiety Disorder/ Panic Disorder/ Social Anxiety Disorder – LIMITED DATA
- PubMed Literature Search
- Ballard ED, Ionescu DF, Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsché NE, Ameli R, Furey ML, Zarate Jr CA. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. Journal of psychiatric research. 2014 Nov 1;58:161-6.
- Banov MD, Young JR, Dunn T, Szabo ST. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS spectrums. 2020 Jun;25(3):331-42.
- Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Voort JL, Brutsche NE, Zarate Jr CA. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. The Journal of clinical psychiatry. 2014 Sep 25;75(9):5470.
- Ray SM, Kious BM. Sustained resolution of panic disorder, agoraphobia, and generalized anxiety disorder with a single ketamine infusion: A case report. The Primary Care Companion for CNS Disorders. 2016 Jul 7;18(4):27235.
Post-Traumatic Stress Disorder (PTSD)
- PubMed Literature Search
- Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, Thuras P, Batres-y-Carr TM, Wels J, Shiroma PR. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. The Journal of clinical psychiatry. 2018 May 1;79(3):17462.
- Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry. 2021 Feb 1;178(2):193-202.
- Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA psychiatry. 2014 Jun 1;71(6):681-8.
- Liriano F, Hatten C, Schwartz TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs in context. 2019;8.
- Norbury A, Rutter SB, Collins AB, Costi S, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Glasgow AM, Brallier J. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology. 2021 Dec;46(13):2266-77.
Substance Use Disorders
- PubMed Literature Search
- Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Molecular psychiatry. 2017 Jan;22(1):76-81.
- Dakwar E, Nunes EV, Hart CL, Hu MC, Foltin RW, Levin FR. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology. 2018 Nov 1;142:270-6.
- Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, Nunes EV. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. American Journal of Psychiatry. 2020 Feb 1;177(2):125-33.
- Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJ, Basaraba CN, Pavlicova M, Levin FR. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. American Journal of Psychiatry. 2019 Nov 1;176(11):923-30.
- Jovaiša T, Laurinėnas G, Vosylius S, Šipylaitė J, Badaras R, Ivaškevičius J. Effects of ketamine on precipitated opiate withdrawal. Medicina (Kaunas). 2006;42(8):625-34.
- Wong A, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Annals of Pharmacotherapy. 2015 Jan;49(1):14-9.
- Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA psychiatry. 2019 Mar 1;76(3):337-8.
Eating Disorders – LIMITED DATA
- PubMed Literature Search
- Hermens DF, Simcock G, Dutton M, Bouças AP, Can AT, Lilley C, Lagopoulos J. Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2020 Jul 13;101:109921.
- Keeler JL, Treasure J, Juruena MF, Kan C, Himmerich H. Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. Nutrients. 2021 Nov;13(11):4158.
- Mills IH, Park GR, Manara AR, Merriman RJ. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM: monthly journal of the Association of Physicians. 1998 Jul 1;91(7):493-503.
- Ragnhildstveit A, Jackson LK, Cunningham S, Good L, Tanner Q, Roughan M, Henrie-Barrus P. Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy. Frontiers in Psychiatry. 2021;12.
Obsessive Compulsive Disorder (OCD) – LIMITED DATA
- PubMed Literature Search
- Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biological psychiatry. 2012 Dec 1;72(11):964-70.
- Rodriguez CI, Wheaton M, Zwerling J, Steinman SA, Sonnenfeld D, Galfalvy H, Simpson HB. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. The Journal of clinical psychiatry. 2016 Mar 23;77(3):7005.
Attention Deficit Hyperactivity Disorder (ADHD) – No Clinical Trials Identified
Autism Spectrum Disorder – No Clinical Trials Identified
Deep Transcranial Magnetic Stimulation
dTMS Key References
- BrainsWay. (n.d.). What evidence exists for Deep TMS effectiveness? BrainsWay. https://www.brainsway.com/patients-faqs/what-evidence-exists-for-deep-tms-effectiveness/
- Gregory, S. T., Goodman, W. K., Kay, B., Riemann, B., & Storch, E. A. (2022). Cost-effectiveness analysis of deep transcranial magnetic stimulation relative to evidence-based strategies for treatment-refractory obsessive-compulsive disorder. Journal of Psychiatric Research, 146, 50–54. https://doi.org/10.1016/j.jpsychires.2021.12.034
- Zangen, A., Zibman, S., Tendler, A., Barnea-Ygael, N., Alyagon, U., Blumberger, D. M., Grammer, G., Shalev, H., Gulevsky, T., Vapnik, T., Bystritsky, A., Filipčić, I., Feifel, D., Stein, A., Deutsch, F., Roth, Y., & George, M. S. (2023, January 24). Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with deep TMS. JCI Insight. Retrieved February 13, 2023, from https://insight.jci.org/articles/view/165271
Ketamine Assisted Therapy
KAP Key References
- Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs, 51(2), 189–198. https://doi.org/10.1080/02791072.2019.1587556
- Joneborg, I., Lee, Y., Di Vincenzo, J. D., Ceban, F., Meshkat, S., Lui, L. M., … & McIntyre, R. S. (2022). Active mechanisms of ketamine-assisted psychotherapy: A systematic review. Journal of Affective Disorders.